France Expands Meningitis Vaccine Coverage: What You Need to Know
In response to a rise in meningitis cases and an ongoing outbreak in the UK, French health authorities have expanded coverage for meningitis vaccines Bexsero and Menveo. These vaccines are now reimbursed by the national health insurance system, offering increased protection against this serious illness.
Expanded Reimbursement Details
Effective March 12, 2026, both Bexsero (protecting against group B meningococcus) and Menveo (covering groups A, C, W, and Y) will be covered for specific patient groups. This includes individuals with certain immune deficiencies, those without a spleen, and patients who have undergone stem cell transplants. A temporary catch-up program is also available for children born in 2020, 2021, and 2022.
Mandatory Vaccination Program
France already has a mandatory vaccination program in place for infants. Since January 1, 2025, vaccination against meningococcal groups ACWY has been required for all newborns. Vaccination against meningococcal group B is also mandatory for babies born after this date.
“In England, the number of novel cases among young children decreased by nearly 80% with a complete vaccination schedule (3 doses against invasive meningococcal B infections) during the first three years of the program… In the Netherlands, the number of new cases among young children decreased by nearly 82% following the replacement of vaccination against meningococcal C with vaccination against meningococcal ACWY,” according to information from the French Ministry of Health.
Rising Meningitis Cases Prompt Action
The decision to expand vaccine coverage comes amid a concerning increase in invasive meningococcal infections. Public Health France reported 616 cases of meningitis in 2024, a 10% increase compared to 2023. This represents the highest annual case count since 2010. Meningitis B is most common in infants and young children aged 1-4, while groups W and Y are more prevalent in infants and the elderly (over 80 years old).
Looking Ahead: Potential Future Trends
The recent expansions and ongoing mandatory vaccination programs signal a proactive approach to meningitis prevention in France. Several trends are likely to shape the future of meningitis control:
- Monovalent Vaccine Development: The approval of a single-dose Menveo formulation in late 2024 suggests a move towards more convenient and accessible vaccination options.
- Broader Age Group Recommendations: Current reimbursement for Menveo extends to individuals aged 11-24. Future recommendations may broaden coverage to include other at-risk populations, such as college students living in dormitories.
- Enhanced Surveillance Systems: Continued investment in robust surveillance systems, like those used by Public Health France, will be crucial for early detection of outbreaks and informed vaccine policy decisions.
- Focus on Vaccine Equity: Ensuring equitable access to vaccines across all socioeconomic groups will be essential to maximize population-level protection.
Frequently Asked Questions (FAQ)
- Who is eligible for the expanded reimbursement? Individuals with specific immune deficiencies, those without a spleen, stem cell transplant recipients, and children born in 2020, 2021, or 2022.
- Is meningitis vaccination mandatory in France? Yes, vaccination against meningococcal groups ACWY and B is mandatory for all infants born on or after January 1, 2023.
- What are the symptoms of meningitis? Symptoms can include fever, headache, stiff neck, nausea, vomiting, and sensitivity to light. Seek immediate medical attention if you suspect meningitis.
Learn more about meningitis and vaccination recommendations from MesVaccins and the French Ministry of Health.
Have questions about meningitis or the new vaccine coverage? Share your thoughts in the comments below!
